PE20120254A1 - Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(trifluorometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona - Google Patents

Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(trifluorometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona

Info

Publication number
PE20120254A1
PE20120254A1 PE2011001528A PE2011001528A PE20120254A1 PE 20120254 A1 PE20120254 A1 PE 20120254A1 PE 2011001528 A PE2011001528 A PE 2011001528A PE 2011001528 A PE2011001528 A PE 2011001528A PE 20120254 A1 PE20120254 A1 PE 20120254A1
Authority
PE
Peru
Prior art keywords
phenyl
etoximethyl
trifluorometil
decan
ona
Prior art date
Application number
PE2011001528A
Other languages
English (en)
Spanish (es)
Inventor
Larisa Reyderman
Zhihui Qiu
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of PE20120254A1 publication Critical patent/PE20120254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2011001528A 2006-04-05 2007-04-04 Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(trifluorometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona PE20120254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78951406P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
PE20120254A1 true PE20120254A1 (es) 2012-03-26

Family

ID=38441502

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001528A PE20120254A1 (es) 2006-04-05 2007-04-04 Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(trifluorometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona
PE2007000412A PE20080054A1 (es) 2006-04-05 2007-04-04 Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(triflourometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000412A PE20080054A1 (es) 2006-04-05 2007-04-04 Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(triflourometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona

Country Status (19)

Country Link
US (4) US7563801B2 (enExample)
EP (2) EP2997964A1 (enExample)
JP (4) JP5155998B2 (enExample)
KR (1) KR20080108319A (enExample)
CN (2) CN101460151B (enExample)
AR (1) AR060303A1 (enExample)
AU (1) AU2007233389C1 (enExample)
BR (1) BRPI0710577A2 (enExample)
CA (2) CA2648640C (enExample)
CL (1) CL2007000945A1 (enExample)
ES (1) ES2553805T3 (enExample)
MX (1) MX2008012936A (enExample)
NO (1) NO342810B1 (enExample)
NZ (1) NZ571693A (enExample)
PE (2) PE20120254A1 (enExample)
SG (1) SG10201500028RA (enExample)
TW (1) TWI332836B (enExample)
WO (1) WO2007114921A2 (enExample)
ZA (1) ZA200808465B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
EP2662374A1 (en) 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor
CL2007000945A1 (es) * 2006-04-05 2008-01-25 Schering Corp Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
WO2010077669A2 (en) * 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
BR112012003263A2 (pt) 2009-08-14 2015-09-22 Opko Health Inc formulações intravenosas de antagonistas de neuroquinina-1
EP3002005A1 (en) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direct compression excipient based on lactose, cellulose and starch
CN104473887A (zh) * 2014-11-12 2015-04-01 广东东阳光药业有限公司 一种提高利伐沙班片溶出曲线重现性的方法
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US431003A (en) * 1890-06-24 Store-service apparatus
GB1605190A (en) * 1968-08-23 1983-03-23 Phillips Petroleum Co Armour plate
US4013613A (en) * 1971-10-01 1977-03-22 General Electric Company Reinforced intercrystalline thermoplastic polyester compositions
US4079161A (en) * 1974-07-12 1978-03-14 Phillips Petroleum Company Transparent oriented polyolefin laminated armor structure
FR2678971B1 (fr) * 1991-07-08 1998-04-10 Andre Giraud Elements de structure composite transparents et leurs procedes de fabrication.
US5830548A (en) * 1992-08-11 1998-11-03 E. Khashoggi Industries, Llc Articles of manufacture and methods for manufacturing laminate structures including inorganically filled sheets
US5665450A (en) * 1992-08-21 1997-09-09 The Curators Of The University Of Missouri Optically transparent composite material and process for preparing same
CA2146767A1 (en) 1992-10-28 1994-05-11 Timothy Harrison 4-arylmethyloxymethyl piperidines as tachykinin antagonists
EP0673367A1 (en) 1992-12-14 1995-09-27 MERCK SHARP & DOHME LTD. 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
JPH09507500A (ja) 1994-01-13 1997-07-29 メルク シヤープ エンド ドーム リミテツド ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬
US5733659A (en) * 1995-02-27 1998-03-31 Mitsubishi Engineering-Plastics Corporation Transparent rigid resin molded product and process for producing the same
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
DE69616367T2 (de) 1995-08-28 2002-06-27 Schering Corp., Kenilworth Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin
US5759658A (en) * 1996-04-26 1998-06-02 Tables International Corporation Composite panels, articles incorporating same and method
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US6630231B2 (en) * 1999-02-05 2003-10-07 3M Innovative Properties Company Composite articles reinforced with highly oriented microfibers
NZ536302A (en) * 1999-03-30 2006-05-26 Schering Corp Cancer treatment regime with temozolomide
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
DE10053151A1 (de) * 2000-10-26 2002-05-08 Bayer Ag Zusammensetzung enthaltend thermoplastische Kunststoffe
CN100509782C (zh) 2001-11-13 2009-07-08 先灵公司 Nk1拮抗剂
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6818306B2 (en) * 2002-09-27 2004-11-16 The Boeing Company Optically clear structural laminate
MXPA06003749A (es) * 2003-10-03 2006-06-14 Pfizer Derivados de tropano.
US6889938B1 (en) * 2003-10-21 2005-05-10 The Boeing Company Structural cockpit window and method of making same
JP2007515425A (ja) * 2003-12-22 2007-06-14 シェーリング　コーポレイション 医薬組成物
MY142804A (en) 2004-07-01 2011-01-14 Opko Health Inc Nk1 antagonists
BRPI0517976A (pt) 2004-11-09 2008-10-21 Schering Corp métodos de tratamento
EP2662374A1 (en) 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor
CL2007000945A1 (es) * 2006-04-05 2008-01-25 Schering Corp Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
BR112012003263A2 (pt) 2009-08-14 2015-09-22 Opko Health Inc formulações intravenosas de antagonistas de neuroquinina-1

Also Published As

Publication number Publication date
JP6035305B2 (ja) 2016-11-30
EP2004148A2 (en) 2008-12-24
AU2007233389B2 (en) 2013-02-28
CA2861281A1 (en) 2007-10-11
WO2007114921A2 (en) 2007-10-11
ES2553805T3 (es) 2015-12-11
JP2012167125A (ja) 2012-09-06
JP5155998B2 (ja) 2013-03-06
NZ571693A (en) 2011-12-22
AU2007233389C1 (en) 2013-07-25
US20120015921A1 (en) 2012-01-19
WO2007114921A3 (en) 2008-03-27
US20070275051A1 (en) 2007-11-29
US7981905B2 (en) 2011-07-19
EP2997964A1 (en) 2016-03-23
HK1133387A1 (en) 2010-03-26
JP2015071603A (ja) 2015-04-16
BRPI0710577A2 (pt) 2011-08-16
US9345692B2 (en) 2016-05-24
JP2013049720A (ja) 2013-03-14
CA2648640A1 (en) 2007-10-11
JP5415587B2 (ja) 2014-02-12
CA2648640C (en) 2016-02-16
US20140088128A1 (en) 2014-03-27
CN103751186A (zh) 2014-04-30
CN103751186B (zh) 2016-08-24
CL2007000945A1 (es) 2008-01-25
NO20084660L (no) 2008-11-04
TW200808312A (en) 2008-02-16
CN101460151A (zh) 2009-06-17
EP2004148B1 (en) 2015-07-15
AU2007233389A1 (en) 2007-10-11
US7563801B2 (en) 2009-07-21
NO342810B1 (no) 2018-08-13
CN101460151B (zh) 2013-11-20
JP2009532473A (ja) 2009-09-10
AR060303A1 (es) 2008-06-04
TWI332836B (en) 2010-11-11
JP5640065B2 (ja) 2014-12-10
MX2008012936A (es) 2008-10-15
PE20080054A1 (es) 2008-02-25
US20100137348A1 (en) 2010-06-03
US8404702B2 (en) 2013-03-26
ZA200808465B (en) 2011-03-30
KR20080108319A (ko) 2008-12-12
SG10201500028RA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
PE20081891A1 (es) Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
PE20080054A1 (es) Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(triflourometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona
NO20084659L (no) Ko-krystall av C-glucosidderivat og L-prolin
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MY153985A (en) Aminotriazole derivatives as alx agonists
GEP20125487B (en) Organic compounds and their use
UY29427A1 (es) Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones
BRPI0613499A8 (pt) formulação de comprimido farmacêutico de 1[(3-hidróxi-adamant-1-ilamino)-acetil]- pirrolidino-2(s)-carbonitrila de liberação modificada, comprimido em multicamada, comprimido farmacêutico e cápsula contendo a mesma, processo de produção da mesma, seu uso, processo de preparação de comprimido bem como forma de dosagem farmacêutica
RU2006146971A (ru) Таблетка с покрытием
UY30334A1 (es) Derivados de triazolopirazina
AR065698A1 (es) Preparacion solida
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
MX2010001574A (es) Ligandos del receptor cannabinoide.
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
GB0607954D0 (en) Organic compounds
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
EA201691869A1 (ru) Стабильная комбинированная фармацевтическая композиция
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
PT103884A (pt) Composições de libertação prolongada e métodos para a sua preparação
BR0313173A (pt) preparação farmacêutica que contém um composto de benzimidazol misto com celulose microcristalina, método para sua preparação, bem como uso da dita celulose microcristalina
ATE451097T1 (de) Valsartanformulierungen

Legal Events

Date Code Title Description
FC Refusal